Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating ...

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...